At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 473 enrolled
Drug / intervention
Vilazodone +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating Vilazodone, Placebo, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 473 participants across 60 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartFeb 2015
Primary CompletionSep 2018
TodayJul 2026
First PostedFeb 26, 2015
Enrollment StartFeb 28, 2015
Primary CompletionSep 11, 2018
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.3 years ago
Interventions
Vilazodonedrug
Placebodrug
Fluoxetinedrug